|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Epicentre Medecins Sans Frontieres |
| Information provided by: | Epicentre |
| ClinicalTrials.gov Identifier: | NCT00489658 |
Purpose
This case series study follows on a terminated randomised clinical trial in a nearby location of Uganda, in which the combination of eflornithine + nifurtimox showed very promising efficacy and safety. The study's purpose is to evaluate the efficacy and safety of this combination in a larger group of late-stage Human African trypanosomiasis (sleeping sickness) patients.
| Condition | Intervention | Phase |
|
Trypanosomiasis, African |
Drug: Eflornithine plus Nifurtimox combination therapy |
Phase II Phase III |
| ChemIDplus related topics: | Eflornithine Nifurtimox |
| Study Type: | Interventional |
| Study Design: | Open Label, Uncontrolled, Single Group Assignment |
| Official Title: | Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda |
| Enrollment: | 31 |
| Study Start Date: | October 2002 |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Uganda, Yumbe District | |||||
| Yumbe District Hospital | |||||
| Yumbe, Yumbe District, Uganda | |||||
| Epicentre |
| Medecins Sans Frontieres |
| Principal Investigator: | Patrice Piola, MD MSc | Epicentre |
| Study Director: | Gerardo Priotto, MD MPH | Epicentre |
More Information
| Study ID Numbers: | NECS |
| First Received: | June 20, 2007 |
| Last Updated: | June 20, 2007 |
| ClinicalTrials.gov Identifier: | NCT00489658 |
| Health Authority: | Uganda: National Council for Science and Technology; Uganda: Ministry of Health |
|
|
|
|
|
|